SABS
SAB Biotherapeutics Inc

1,656
Loading...
Loading...
News
all
press releases
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
chainwire·5mo ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Forecasted to Post Q1 2024 Earnings of ($0.98) Per Share
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2024 earnings per share estimates for SAB Biotherapeutics in a research note...
Zolmax·1y ago
News Placeholder
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...
Globe Newswire·2y ago
News Placeholder
SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
SAB Biotherapeutics ( NASDAQ:SABS ) Full Year 2023 Results Key Financial Results Net loss: US$42.2m (loss widened by...
Simply Wall St·2y ago
News Placeholder
SAB Biotherapeutics GAAP EPS of -$7.64 misses by $3.43, revenue of $2.24M beats by $1.12M
SAB Biotherapeutics GAAP EPS of -$7.64 misses by $3.43, revenue of $2.24M beats by $1.12M...
SeekingAlpha.com: All News·2y ago
News Placeholder
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...
Globe Newswire·2y ago
News Placeholder
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ( SAB or the Company ), a clinical-stage biopharmaceutical company with a novel immunotherapy...
Globe Newswire·2y ago
News Placeholder
SAB Biotherapeutics Secures Leadership with New Executive Contracts
SAB Biotherapeutics (SABS) has issued an update. SAB Biotherapeutics, Inc. has entered into new executive employment agreements with Eddie J. Sulli...
TipRanks Financial Blog·2y ago
News Placeholder
Analyzing SAB Biotherapeutics (NASDAQ:SABS) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF)
SAB Biotherapeutics (NASDAQ:SABS Get Free Report) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF Get Free Report) are both medical companies, but which is the superior business? We...
Zolmax·2y ago

Latest SABS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.